Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Compare findings
Compare selected psilocybin depression and alcohol-use reports by population, design, sample, endpoint, finding and limitations with original source links.
Free access · No subscription for research tools or data exports
Compare selected original reports
This educational comparison reuses the original annotations in our evidence guides. It is a selected set, not a systematic review or an independently clinically reviewed treatment recommendation. Source-check dates belong to the annotations and do not advance when the page is rebuilt.
| Report and population | Design and sample | Endpoint | Finding | Limitations |
|---|---|---|---|---|
| Johnson et al. · 2026 randomized pilot Psychiatrically healthy adult cigarette smokers Source checked 2026-10-09 | Open-label randomized comparison: one psilocybin session versus nicotine patches; both groups received manualized cognitive behavioral therapy 82 randomized: 42 psilocybin, 40 nicotine patch | Biochemically verified prolonged abstinence at six months; intention-to-treat analysis | Primary abstinence comparison favored psilocybin 17/42 (40.5%) versus 4/40 (10.0%): odds ratio 6.12, 95% CI 1.99–23.26, p=0.003. Seven-day point-prevalence abstinence was a separate secondary endpoint. | Unblinded pilot at one centre, with different treatment contact time and a selected population. It does not compare against every established cessation treatment. No serious events were attributed to either intervention; this does not establish absence of rare harms. |
| Johnson et al. · 2014 pilot Nicotine-dependent smokers with previous quit attempts Source checked 2026-10-09 | Open-label single-group psilocybin programme with cognitive behavioral therapy 15 participants; no randomized comparator | Biologically verified seven-day point-prevalence abstinence at six months | Preliminary uncontrolled finding 12/15 participants (80%) met this abstinence definition at six months. | A seven-day window does not mean continuous abstinence. Without a concurrent control, the contribution of psilocybin, therapy and selection cannot be separated. |
| Johnson et al. · 2017 follow-up The same 15-person cohort as the 2014 pilot Source checked 2026-10-09 | Longer follow-up of the earlier uncontrolled programme; not an independent trial 15 assessed at 12 months; 12 returned for later follow-up | Biologically verified abstinence at 12 months and longer-term assessment | Follow-up of the original cohort 10/15 (67%) were abstinent at 12 months; 9/15 (60%) at longer follow-up, averaging 30 months after the target quit date. | Attrition and lack of a control remain. Counting this report and the 2014 pilot as separate participant cohorts would double-count evidence. |
3 reports shown